- Home
- CNTY vs TLSA Comparison
CNTY vs TLSA Comparison
Compare CNTY & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | TLSA |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 145.1M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTY | TLSA |
|---|---|---|
| Price | $1.12 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 611.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.14 | $0.87 |
| 52 Week High | $2.80 | $2.35 |
Technical Indicators
Market Signals| Indicator | CNTY | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $1.33 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.